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**Additional file 1.** Full protocol.
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We acknowledge Cancer Research UK (CRUK) who, during the COVID-19 crisis, allowed its staff at Southampton CTU to work with the National Institute for Health Research (NIHR) community (e.g. Southampton CTU, Liverpool CRF & Southampton Biomedical Research Centre) to develop this phase I/II trial platform. We also acknowledge the University Hospital Southampton NHS Foundation Trust, Liverpool University Hospitals NHS Foundation Trust, University of Southampton and the University of Liverpool who supported and collaborated in the development of AGILE-ACCORD.

GG, SK and RF came up with the concept of the development of AGILE-ACCORD and oversaw the development of the master protocol and this submission. TJ was responsible for the development of the statistical design and SE/LS the statistical aspects of running and analysing the trial. EM, AC, HR, LW were responsible for developing the trial management and delivery aspects of the trial. SC, EW, AN, MR and RDD were responsible for the development of data collection and management aspects of the trial. SY was responsible for quality assurance and pharmacovigilance aspects of the study and JR operational aspects. All were involved in the development of the master protocol and this submission. The author(s) read and approved the final manuscript.
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GG (Director of the NIHR/CRUK Southampton Clinical Trials Unit), RF (Director of the NIHR Clinical Research Facility (CRF) in Liverpool) and SK (Chief Investigator of AGILE-ACCORD) have developed this master protocol for, and on behalf, the UK NIHR and CRF community and COVID-19 patients. Although we intend to run AGILE-ACCORD in the UK we invite researchers around the world (especially low and middle income countries) to use our master protocol as a template to help conduct their own COVID-19 research in their own countries.

The development of the AGILE-ACCORD Master Protocol, electronic data capture system, randomisation and econsent was funded using Cancer Research UK core funding and NIHR CTU support funding at the Southampton Clinical Trials Unit. NIHR funding at the Royal Liverpool and Broadgreen Clinical Research Facility and staff at the University of Liverpool and Lancaster also supported the development of the master protocol and its associated documentation (eg participant information sheets, case report forms). Funding for each Candidate Specific Trial protocol is expected to be a mixture of NIHR, UKRI and investigator initiated research grants from pharmaceutical companies supplying the candidate.

When the database from each Candidate Specific Trial Protocol is locked, analysed and published we will make the data available to the academic community via [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com)
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I certify that this trial has received appropriate ethical approval as described above.

We will obtain consent from all participants entering into AGILE_ACCORD. If the patient lacks capacity to give consent due to the severity of their medical condition (e.g. patients with WHO clinical severity scores of 6 (hospitalised, intubation and mechanical ventilation) and 7 (ventilation and additional organ support -- pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO)), then in the first instance, consent may be obtained from the patient's personal legal representative.
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